LDS/Medical Tests/HLA-B75 (HLA-B*15:02) Genotyping for Carbamazepine Hypersensitivity

HLA-B75 (HLA-B*15:02) Genotyping for Carbamazepine Hypersensitivity

Carbamazepine is an anticonvulsant and mood-stabilizing drug that is FDA-approved for treatment of epilepsy, trigeminal neuralgia and bipolar disorder. One of the more severe side-effects of carbamazepine is Stevens - Johnson syndrome (SJS), a life-threatening skin condition. SJS is estimated to occur in 1–6 per 10,000 new users of carbamazepine in countries with mainly Caucasian populations, but the risk in some Asian populations is estimated to be about 10 times higher.

Carbamazepine-induced SJS is strongly associated with the HLA-B*15:02 (B75) allele. HLA-B is a part of the MHC class I antigen-presenting receptor (also called the human leukocyte antigen) system and distinguishes cells between self and non-self for the purposes of the immune system. HLA-B*15:02 (B75) genotyping identifies persons at high risk of developing SJS in response to Carbamazepine therapy.

The FDA recommends that individuals of Asian ancestry be genotyped for the presence of the HLA-B*1502 allele prior to receiving Carbamazepine. Phenytoin and its soluble precursor fosphenytoin (drugs used to control seizures) are also associated with the HLA-B*1502 allele and Stevens Johnson Syndrome in certain Asian population.

According to the most recent Clinical Pharmacogenetic Implementation Consortium (CPIC) guideline, patients who are HLA-B15:02 positive should not be prescribed carbamazepine or oxcarbamazepine if alternative agents are available; however, caution should be used in selecting an alternative medication as there is weaker evidence that also links other aromatic anticonvulsants with SJS/TEN in patients positive for HLA-B15:02.

  • Risk assessment for Cabamazepine therapy induced Stevens-Johnson Syndrome
  • Genetic screening for the presence of the HLA-B*1502 in Asians before receiving Carbamazepine or Phenytoin (and its soluble precursor Fosphenytoin)
The presence of the HLA-B\*15:02 (B75) allele confers a high risk of Carbamazepine induced SJS and an alternative drug therapy should be used.

Negative for HLA-B\*15:02

Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probe (SSO), Polymerase Chain Reaction (PCR)/Sequence Specific Primer Extension, Direct sequencing.

Whole blood (ACD yellow top tube is preferred, EDTA lavender top tube also accepted). 

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Carbamazepine, Phenytoin.
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login